{
    "paper_id": "PMC7097449",
    "metadata": {
        "title": "The business of making vaccines",
        "authors": [
            {
                "first": "Cormac",
                "middle": [],
                "last": "Sheridan",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Vaccine franchises and increases to manufacturing capacity by the top five vaccine producers\nSource: Company websites and World Health Organization (WHO), http://www.who.int/vaccine_research/documents/en/Status_Table_April05.pdf",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: Manufacturing processes for vaccines\nSource: WHO, http://www.who.int/vaccines-access/quality/contractmanufdb/vaccinetypes_processes.htm and Immunization Action Coalition (St. Paul, MN, USA)",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 3: Selected biotech companies dedicated to the research, development and manufacture of prophylactic vaccines\n",
            "type": "table"
        },
        "TABREF3": {
            "text": "Table 4: Selected public biotech companies with a business interest in prophylactic vaccine development\n",
            "type": "table"
        },
        "TABREF4": {
            "text": "Table 5: Selected private biotech companies with a business interest in prophylactic vaccine development\n",
            "type": "table"
        },
        "TABREF5": {
            "text": "Table 6: Selected vaccine supply contracts for project BioShield\nSource: US Department of Health & Human Services. aOriginal order for 209 million doses cut to 182.5 million doses. bGrants shared by two companies, individual grant not disclosed.",
            "type": "table"
        },
        "TABREF6": {
            "text": "Table 7: Biotech companies with Bioshield vaccine projects\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: Source: GSK, Brentford, UK. http://www.gsk.com/financial/presentations/vaccines2005/Flu.pdf",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "",
            "authors": [
                {
                    "first": "FM",
                    "middle": [],
                    "last": "Scherer",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "American Anti-Trust Institute Working Paper 04-03 29",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Heterologous protection against influenza by infection of DNA encoding a viral protein",
            "authors": [
                {
                    "first": "JB",
                    "middle": [],
                    "last": "Ulmer",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "Science",
            "volume": "259",
            "issn": "",
            "pages": "1691-1692",
            "other_ids": {
                "DOI": [
                    "10.1126/science.8456302"
                ]
            }
        }
    }
}